Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company ...

ARLINGTON, Mass. - KALA BIO, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on developing treatments for rare and severe eye diseases, announced a change in its executive leadership on Monday ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and ...

Fluorescein sodium dissolved in saline served as a control. The fluorescent intensity of the precorneal tear film was measured at the central cornea every minute for 10 min. The turnover rate was ...

Patients with limbal deficiency may benefit from limbal stem cell transplantation to alleviate persistent epithelial defects, maintain conjunctivalization regression and corneal avascularity ...

On the left eye, the patient had conjunctival congestion and hyperemia, a central 2- × 2-mm corneal epithelial defect with deep stromal infiltration, endothelial plaque, moderate anterior chamber ...

In vitro assays using human corneal epithelial cells-transformed (HCE-T ... as a novel strategy to accelerate healing of corneal defects while mitigating vision impairment (Scheme 1). Hemoglobin ...

Lufepirsen is under clinical development by Amber Ophthalmics and currently in Phase II for Persistent Corneal Epithelial Defects. According to GlobalData, Phase II drugs for Persistent Corneal ...